ScoreWhy is Sun Pharmaceutical Industries Ltd ?
1
Low Debt Company with Strong Long Term Fundamental Strength
- Healthy long term growth as Net Sales has grown by an annual rate of 10.95% and Operating profit at 15.04%
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 15.58% signifying high profitability per unit of shareholders funds
2
High Institutional Holdings at 36.71%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
4
Market Beating performance in long term as well as near term
- Along with generating 21.35% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
5
With its market cap of Rs 4,66,431 cr, it is the biggest company in the sector and constitutes 16.74% of the entire sector
- Its annual Sales of Rs 59,910.52 are 12.10% of the industry
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Sun Pharma.Inds. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sun Pharma.Inds. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Sun Pharma.Inds.
21.31%
1.11
19.19%
Sensex
-2.73%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.95%
EBIT Growth (5y)
15.04%
EBIT to Interest (avg)
52.37
Debt to EBITDA (avg)
0.26
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.71
Tax Ratio
24.13%
Dividend Payout Ratio
35.13%
Pledged Shares
1.65%
Institutional Holding
36.71%
ROCE (avg)
22.23%
ROE (avg)
15.58%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
37
Industry P/E
37
Price to Book Value
5.58
EV to EBIT
29.49
EV to EBITDA
24.57
EV to Capital Employed
7.88
EV to Sales
7.32
PEG Ratio
3.64
Dividend Yield
0.82%
ROCE (Latest)
26.58%
ROE (Latest)
14.92%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
No Trend
OBV
Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
NO KEY POSITIVE TRIGGERS
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is not working for Sun Pharma.Inds.
Non Operating Income - Quarterly
Highest at Rs 723.62 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
